The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy
Abstract
Objectives: To study the safety and efficacy of continuous intratympanic dexamethasone‐phosphate (Dex‐P) for severe to profound sudden idiopathic sensorineural hearing (ISSHL) or sudden idiopathic anacusis after failure of systemic therapy. Study Design: Randomized, double‐blind, placebo controlled multicenter trial. Methods: Patients with ISSHL and insufficient recovery (mean 4PTA = 97 dB HL) after systemic high dose glucocorticoid therapy received either Dex‐P (4mg/ml) or placebo (NaCl 0.9%) continuously applied for 14 days into the round window niche via a temporarily implanted catheter. For ethical reasons, intratympanic treatment was continued with Dex‐P in all patients for another 14 days after the placebo‐controlled study period. According to a two‐step adaptive study design an interim analysis was performed after inclusion of 23 patients. Results: Intention‐to‐treat analysis for the primary outcome criterion (4PTA: 0.5‐3kHz) during the placebo controlled study period (14 days) showed an average hearing improvement in the treatment group of 13.9 dB (SD: 21.3) and in the placebo group of 5.4 dB (SD: 10.4). This difference in hearing improvement between the two groups (mean: 8.4 dB, SD: 17.0, 95% CI: −7.1–24.1) was statistically not significant (p = .26). Of the secondary outcome parameters, the largest benefit of local salvage therapy was found for maximum speech discrimination with an improvement of 24.4% (SD: 32.0) in the treatment and 4.5% (SD: 7.6) in the placebo group (p = 0.07). After a 3 month follow‐up period (i.e. after all patients received intratympanic Dex‐P) hearing improvement in the two groups was very similar. No serious adverse events were observed. Sample size calculation after the interim analysis resulted in stopping of the trial. Conclusions: The tendency toward better hearing improvement in the treatment group, the rather conservative inclusion criteria, the limited placebo‐controlled observation period and the absence of serious adverse events supports further investigation local inner ear drug delivery as a first or second line treatment option for ISSHL. Laryngoscope, 119:359–369, 2009
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
Natural history of sudden sensorineural hearing loss
Mattox, D. E., & Simmons, F. B. (1977) · Annals of Otology, Rhinology & Laryngology · doi:10.1177/000348947708600406 · Cited by 833 · cited 1×
“Only one patient attained an absolute pure tone threshold (4 PTA) of 40 dB HL after the placebo controlled treatment phase of the trial and one in each group at follow-up.(45) It was difficult to calculate outcome based on pure tone audiometry for those patients with nonmeasurable hearing levels in the audiogram (‘‘an…”
BackgroundParnes, L. S., Sun, A., & Freeman, D. J. (1999) · The Laryngoscope · doi:10.1097/00005537-199907001-00001 · Cited by 634
Cited by
Clinical Practice Guideline: Sudden Hearing Loss
Stachler, R. J., Chandrasekhar, S. S., Archer, S. M., Rosenfeld, R. M., Schwartz, S. R., Barrs, D. M., Brown, S. R., Fife, T. D., Ford, P., Ganiats, T. G., et al. (2012) · Otolaryngology–Head and Neck Surgery · doi:10.1177/0194599812436449 · Cited by 971
Sudden sensorineural hearing loss
Schreiber, B. E., Agrup, C., Haskard, D. O., & Luxon, L. M. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62071-7 · Cited by 554
Sudden Sensorineural Hearing Loss: A Review of Diagnosis, Treatment, and Prognosis
Kuhn, M., Heman-Ackah, S. E., Shaikh, J. A., & Roehm, P. C. (2011) · Trends in Amplification · doi:10.1177/1084713811408349 · Cited by 492
Steroids for idiopathic sudden sensorineural hearing loss
Wei, B. P., Stathopoulos, D., & O'Leary, S. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003998.pub3 · Cited by 354
Delivery of therapeutics to the inner ear: The challenge of the blood-labyrinth barrier
Nyberg, S., Abbott, N. J., Shi, X., Steyger, P. S., & Dabdoub, A. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aao0935 · Cited by 336
Principles of Local Drug Delivery to the Inner Ear
Salt, A. N., & Plontke, S. K. (2009) · Audiology and Neurotology · doi:10.1159/000241892 · Cited by 253
Self-citationInternational consensus (ICON) on treatment of sudden sensorineural hearing loss
Marx, M., Younes, E., Chandrasekhar, S. S., Ito, J., Plontke, S., O’Leary, S., & Sterkers, O. (2018) · European Annals of Otorhinolaryngology, Head and Neck Diseases · doi:10.1016/j.anorl.2017.12.011 · Cited by 152
Self-citationCrane, R. A., Camilon, M., Nguyen, S., & Meyer, T. A. (2015) · The Laryngoscope · doi:10.1002/lary.24834 · Cited by 120
Tandon, V., Kang, W. S., Robbins, T. A., Spencer, A. J., Kim, E. S., McKenna, M. J., Kujawa, S. G., Fiering, J., Pararas, E. E. L., Mescher, M. J., et al. (2016) · Lab on a Chip · doi:10.1039/c5lc01396h · Cited by 73
Liebau, A., Pogorzelski, O., Salt, A. N., & Plontke, S. K. (2017) · Otology & Neurotology · doi:10.1097/mao.0000000000001254 · Cited by 54
Self-citation
Metadata
- Authors
- Plontke, S. K., Löwenheim, H., Mertens, J., Engel, C., Meisner, C., Weidner, A., Zimmermann, R., Preyer, S., Koitschev, A., & Zenner, H.
- Venue
- The Laryngoscope
- Publisher
- Wiley
- Published
- 2009-01-26
- Volume
- 119
- Issue
- 2
- Pages
- 359-369
- ISSN
- 0023-852X (ISSN-L)
- 1531-4995
- OpenAlex
- W2164467019
- Cited by
- 163
- References
- 3
- FWCI
- 11.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.